AMG National Trust Bank Purchases Shares of 14,550 EQRx, Inc. (NASDAQ:EQRX)

AMG National Trust Bank acquired a new position in shares of EQRx, Inc. (NASDAQ:EQRX – Get Rating) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 14,550 shares of the company’s stock, valued at approximately $72,000.

Several other hedge funds also recently made changes to their positions in EQRX. Bank of New York Mellon Corp purchased a new position in shares of EQRx during the first quarter worth about $415,000. Citigroup Inc. purchased a new position in shares of EQRx during the first quarter worth about $116,000. BlackRock Inc. purchased a new position in shares of EQRx during the first quarter worth about $13,021,000. Vanguard Group Inc. purchased a new position in shares of EQRx during the first quarter worth about $12,131,000. Finally, Penserra Capital Management LLC grew its holdings in shares of EQRx by 69.8% during the first quarter. Penserra Capital Management LLC now owns 20,588 shares of the company’s stock worth $85,000 after buying an additional 8,462 shares during the last quarter. Hedge funds and other institutional investors own 82.61% of the company’s stock.

EQRx Stock Down 1.6 %

Shares of EQRX opened at $2.46 on Wednesday. The stock’s 50 day moving average is $2.82 and its two-hundred day moving average is $4.24. EQRx, Inc. has a twelve month low of $1.87 and a twelve month high of $6.05.

EQRx (NASDAQ:EQRX – Get Rating) last posted its quarterly earnings results on Thursday, November 10th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.03. As a group, analysts anticipate that EQRx, Inc. will post -0.71 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on EQRX shares. The Goldman Sachs Group lowered EQRx from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $8.00 to $5.00 in a report on Friday, November 11th. Jefferies Financial Group lowered EQRx from a “buy” rating to a “hold” rating and lowered their price target for the stock from $5.60 to $3.20 in a report on Friday, November 11th. Finally, JPMorgan Chase & Co. lowered EQRx from a “neutral” rating to an “underweight” rating in a report on Monday, November 14th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $4.57.

EQRx Company Profile

(Get Rating)

EQRx, Inc, a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC.